Welcome to our dedicated page for Biodexa Pharmaceuticals plc SEC filings (Ticker: BDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Biodexa Pharmaceuticals plc (NASDAQ: BDRX) SEC filings page on Stock Titan provides direct access to the company’s US regulatory disclosures as a foreign private issuer. Biodexa reports to the Securities and Exchange Commission primarily through Form 20-F for its annual report and Form 6-K for current reports on material developments. These filings document clinical, regulatory and financing milestones for its lead programs eRapa, tolimidone and MTX110.
Recent Form 6-K filings describe key events such as the approval of a Clinical Trial Application (CTA) by the European Medicines Agency for the pivotal Phase 3 Serenta trial of eRapa in familial adenomatous polyposis (FAP), enrollment of the first patients into that trial, and related press releases. Other 6-Ks outline corporate actions including ADR ratio changes, results of the company’s annual general meeting, and details of capital-raising transactions like equity line of credit arrangements and a best-efforts public offering of ADS Units and pre-funded units with accompanying Series L warrants.
Through these filings, investors can review information on offering structures, warrant terms, use of proceeds, grant funding supporting the eRapa FAP program, and updates on cash and cash equivalents at specified dates. The exhibits attached to 6-Ks often include full text of securities purchase agreements, placement agency agreements and warrant forms, providing additional detail on financing terms.
Stock Titan enhances access to BDRX filings with real-time updates from EDGAR and AI-powered summaries that explain the key points of lengthy documents such as current reports and registration-related materials. Users can quickly understand how new financings, clinical trial milestones or regulatory approvals described in Form 6-K may relate to Biodexa’s broader development strategy, while still having the option to read the full SEC documents for complete context.
Biodexa Pharmaceuticals PLC is registering for resale up to 299,261,540,000 ordinary shares represented by 2,992,615 American Depositary Shares previously or potentially issued under a January 17, 2025 Purchase Agreement with C/M Capital Master Fund, LP.
This Post-Effective Amendment No. 2 updates the Form F-1 to include information from the Company’s Form 20-F for the year ended December 31, 2025 and updated selling shareholder disclosures. No new securities are being registered by this amendment; the prospectus covers resale of Depositary Shares issuable under the existing Equity Financing arrangement. The Company states it may receive up to $35.0 million gross under the Purchase Agreement depending on future sales, and that it will not receive proceeds from sales by the Selling Shareholder in this resale registration.
Biodexa Pharmaceuticals PLC filed Post-Effective Amendment No. 3 to a Form F-1 to update its registration statement and prospectus with 2025 annual report information and selling shareholder updates. The prospectus registers for resale 171,700,000 Ordinary Shares represented by 1,717 American Depositary Shares, issuable upon exercise of pre-funded warrants from a December 2023 private placement.
The company states it will receive no proceeds from these resale transactions and that all net proceeds will go to the selling shareholders; proceeds from cash exercises of the warrants would be payable to the company at an exercise price of $0.025 per Ordinary Share. Shares outstanding were 324,156,808,922 Ordinary Shares as of March 12, 2026.
Biodexa Pharmaceuticals PLC filed a Post-Effective Amendment No. 1 to its Form F-1 to register the issuance of Depositary Shares issuable upon exercise of remaining warrants from its December 2025 offering: up to 489,000 Depositary Shares (48,900,000,000 Ordinary Shares underlying Pre-Funded Warrants), up to 6,097,562 Depositary Shares (609,756,200,000 Ordinary Shares underlying Series L Warrants), and up to 152,439 Depositary Shares (15,243,900,000 Ordinary Shares underlying Placement Agent Warrants). No additional securities are being registered beyond those warrants; the amendment concerns only shares issuable on exercise of outstanding warrants. The prospectus states estimated net proceeds of approximately $20.0 million if all Pre-Funded and Series L Warrants are exercised for cash, and an additional $0.5 million if all Placement Agent Warrants are exercised for cash. The Company’s Depositary Shares trade on NASDAQ under BDRX, with a reported close of $0.6603 on March 26, 2026.
Biodexa Pharmaceuticals PLC files Post-Effective Amendment No. 2 to its Form F-1 to update the prospectus and continue the resale registration for 1,701,800,000 ordinary shares represented by 17,018 American Depositary Shares issuable upon exercise of Series J warrants. The company states we will not receive any proceeds from resale by the selling shareholders; proceeds from any cash exercise of the Series J warrants would be received by the company. Shares outstanding were 324,156,808,922 Ordinary Shares as of March 1, 2026. The prospectus notes the Depositary Shares trade on NASDAQ under BDRX and quotes a last reported closing price of $0.6603 on March 26, 2026.
Biodexa Pharmaceuticals PLC filed Post-Effective Amendment No. 3 to its Form F-1 to update its prospectus and include information from its 2025 Form 20-F; no new securities are being registered. This amendment covers the resale of 109,800,000 Ordinary Shares represented by 1,098 Depositary Shares issuable upon exercise of Series D warrants.
The prospectus states the Company will receive no proceeds from resale by the selling shareholders; proceeds would go to those holders unless Series D warrants are exercised for cash. Each Depositary Share represents 100,000 Ordinary Shares. Ordinary Shares outstanding were 324,156,808,922 as of March 12, 2026.
Biodexa Pharmaceuticals PLC files Post-Effective Amendment No. 2 to a Form F-1 to update its resale prospectus. The registration covers an aggregate of 943,400,000 Ordinary Shares represented by 9,434 American Depositary Shares, each ADS representing 100,000 Ordinary Shares. The company will not receive proceeds from resale by the selling shareholders; proceeds from any cash exercise of warrants would be received by the company.
This amendment updates information including the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2025 and selling shareholder details; no additional securities are being registered.
Biodexa Pharmaceuticals PLC, a UK-based early-stage biopharmaceutical company, files its annual report for the year ended December 31, 2025. The group reports net losses of £6.25 million in 2025, £5.73 million in 2024 and £7.08 million in 2023, leading to an accumulated deficit of £155.67 million as of December 31, 2025.
Cash and cash equivalents were £8.53 million at year-end 2025, and management states that additional financing will be required before the third quarter of 2026, creating material uncertainty and substantial doubt about the company’s ability to continue as a going concern. Biodexa has a $35.0 million equity line of credit, under which it has sold $8.92 million of shares, but there is no assurance this will be sufficient.
The company has no recurring revenue and depends on successfully developing and licensing its product candidates, such as eRapa, MTX240 and tolimidone, in a highly competitive and heavily regulated environment. Biodexa also highlights prior material weaknesses in internal controls, complex capital structure changes, extensive shareholder approvals for new shares and significant clinical, regulatory, reimbursement and collaboration risks typical of small biotechnology issuers.
Biodexa Pharmaceuticals reported a 2025 net loss of £6.38 million, with cash and cash equivalents of £8.53 million at year-end and a net cash inflow of £6.87 million driven by £13.04 million of financing inflows.
Research and development spending fell 27% to £3.96 million as MTX110 was removed from the pipeline, while administrative costs rose 27% to £4.84 million, mainly from professional and financing-related fees and foreign exchange movements. The company is advancing eRapa into a registrational Phase 3 FAP trial, supporting a fully enrolled Phase 2 NMIBC study, progressing a Phase 2a T1D study for tolimidone, and has in-licensed MTX240 for GIST.
Management and auditors highlight a material uncertainty around going concern, as forecasts show additional funding will be required in Q3 2026 despite access to a $35.0 million equity line of credit, of which $26.08 million remained undrawn at 31 December 2025.
Biodexa Pharmaceuticals Plc director Stephen Barry Parker filed an initial statement of ownership showing holdings of a stock option over 576 American Depositary Shares. The option has an exercise price of $475.0000 per ADS and expires on January 23, 2034.
The shares underlying this option vest over four years, with 25% vesting on the one-year anniversary of grant and 6.25% vesting every three months thereafter, subject to his continued service. Each American Depositary Share represents 100,000 ordinary shares of Biodexa.
Biodexa Pharmaceuticals is changing the ratio of its American Depositary Receipts to consolidate ADRs and support compliance with Nasdaq listing rules. Each ADR will shift from representing 100,000 ordinary shares to representing 500,000 ordinary shares, with the change expected to take effect on or about April 6, 2026.
ADR holders must surrender their existing ADRs and will receive one new ADR for every five old ADRs. No fractional ADRs will be issued; any aggregated fractions will be sold and the net cash distributed to entitled holders. This operates like a one-for-five reverse ADR split and does not affect the underlying ordinary shares. The company states the change is intended to help its ADR price meet Nasdaq’s $1.00 minimum bid requirement but gives no assurance this objective will be achieved.